Submit Content
Get the latest delivered to your inbox
Privacy Policy

Viatris

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn, Instagram and YouTube.

    Reflections on UNGA 2023: The Time for Action Is Now Image

    POSTED 

    11-02-23

    Reflections on UNGA 2023: The Time for Action Is Now

    We are now at the midpoint of the Sustainable Development Goals (SDGs) timeline, and a key takeaway of UN General Assembly (UNGA) 2023 discussions is that there is still much work to be done. The latest UN data illustrates that progress on 80% of the SDGs is lacking.
    Viatris To Host Webinar: The Power of Partnership To Address Antimicrobial Resistance Image

    POSTED 

    10-31-23

    Viatris To Host Webinar: The Power of Partnership To Address Antimicrobial Resistance

    Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today it is hosting The Power of Partnership to Address Antimicrobial Resistance (AMR), a Nasdaq webinar that will air on Tuesday, November 14, 2023 at 9 a.m. ET.
    Viatris Named to 3BL’s 100 Best Corporate Citizens of 2023 Ranking Image

    POSTED 

    10-30-23

    Viatris Named to 3BL’s 100 Best Corporate Citizens of 2023 Ranking

    Viatris Inc. (NASDAQ: VTRS) announced it has been named to 3BL's annual 100 Best Corporate Citizens ranking, recognizing outstanding environmental, social and governance (ESG) transparency and performance among the 1,000 largest U.S. public companies.
    Viatris Named to Forbes’ Annual List of the World’s Best Employers for the Third Year in a Row Image

    POSTED 

    10-26-23

    Viatris Named to Forbes’ Annual List of the World’s Best Employers for the Third Year in a Row

    Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2023.
    Viatris 2022 Sustainability Report: Water and Waste Image

    POSTED 

    10-24-23

    Viatris 2022 Sustainability Report: Water and Waste

    Guided by our Global Water Policy and global EHS management system, we work to advance responsible water stewardship in our operations and support communities’ access to clean water and sanitation.
    Breaking Barriers: The Crucial Role of Partnerships in Addressing Mental Health and Stigma Image

    POSTED 

    10-18-23

    Breaking Barriers: The Crucial Role of Partnerships in Addressing Mental Health and Stigma

    World Mental Health Day is a global initiative that takes place annually in October and reminds us of the importance of addressing mental health issues and breaking the stigma surrounding them.
    Viatris 2022 Sustainability Report: Big Steps Toward a Smaller Footprint Image

    POSTED 

    10-13-23

    Viatris 2022 Sustainability Report: Big Steps Toward a Smaller Footprint

    As a healthcare company with a global reach, we are committed to taking action against climate change, which poses health dangers on a worldwide scale.
    Building Pandemic Preparedness Image

    POSTED 

    09-19-23

    Building Pandemic Preparedness

    At Viatris, we are working with stakeholders across the globe to prepare for future pandemics. The work includes understanding how healthcare providers and systems can better help patients and respond to the needs of communities.
    Viatris 2022 Sustainability Report: Building Foundations To Advance Diversity, Equity and Inclusion Image

    POSTED 

    09-11-23

    Viatris 2022 Sustainability Report: Building Foundations To Advance Diversity, Equity and Inclusion

    Viatris provides resources for colleagues and managers to connect, set goals aligned to company priorities, discuss career aspirations and development plans, and track progress throughout the year.
    Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-Daily Treatment for Children Living With HIV Image

    POSTED 

    09-06-23

    Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-Daily Treatment for Children Living With HIV

    Viatris Inc. today announced U.S. Food and Drug Administration (FDA) tentative approval for a New Drug Application for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients.
    Viatris logo

    Viatris

    Viatris

    Join today and get the latest delivered to your inbox